Please be informed that Aerami Therapeutics, Inc. has concluded operations. For any inquiries or assistance, please direct your communications to

Breathing Life Into the Treatment of Serious and Rare Cardiopulmonary Diseases

Our Mission

Aerami’s mission-driven approach to product development seeks to help patients live longer and live better by developing inhaled medications that leverage advanced administration platforms to support ease of use and quality of life.

Our Focus

We are developing therapies to address the unmet medical needs of people with serious and rare forms of pulmonary hypertension, including pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension.

An Innovative Approach to Pulmonary Hypertension

AER-901 is a drug-device combination product candidate that is designed to efficiently deliver imatinib deep into the diseased tissues of the lungs. AER-901 is composed of a proprietary, liquid formulation of imatinib for inhalation that is administered by a breath-activated, high-performance, handheld, smart nebulizer that controls flow rate and provides real-time feedback to help optimize lung deposition.